Corrina S. Fonseca

Corrina S. Fonseca

Auto-generated profile, based on publicly available information

Corrina S. Fonseca

University of California, Berkeley, Berkeley, CA USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CFCorrina S. Fonseca
Corrina S. Fonseca
SBSuzanne L. Baker
Suzanne L. Baker
LDLindsey Dobyns
Lindsey Dobyns
MJMustafa Janabi
Mustafa Janabi
WJWilliam J. Jagust
William J. Jagust
THTheresa M. Harrison
Theresa M. Harrison
INTRODUCTION: Amyloid beta (Aβ) and tau pathology are cross‐sectionally associated with atrophy and cognitive decline in aging and Alzheimer's disease (AD).METHODS: We investigated relationships between concurrent longitudinal measures of Aβ (Pittsburgh compound B [PiB] positron emission tomography [PET]), tau (flortaucipir [FTP] PET), atrophy (structural magnetic resonance imaging), episodic memory (EM), and non‐memory (NM) in 78 cognitively healthy older adults (OA).RESULTS: Entorhinal FTP change was correlated with EM decline regardless of Aβ, but meta‐temporal FTP and global PiB change were only associated with EM and NM decline in Aβ+ OA. Voxel‐wise analyses revealed significant associations between temporal lobe FTP change and EM decline in all groups. PiB and FTP change were not associated with structural change, suggesting a functional or microstructural mechanism linking these measures to cognitive decline.DISCUSSION: Our results show that longitudinal Aβ is linked to cognitive decline only in the presence of elevated Aβ, but longitudinal temporal lobe tau is associated with memory decline regardless of Aβ status.Highlights: Entorhinal tau change was associated with memory decline in older adults (OA), regardless of amyloid beta (Aβ). Greater meta‐region of interest (ROI) tau change correlated with memory decline in Aβ+ OA. Voxel‐wise temporal tau change correlated with memory decline, regardless of Aβ. Meta‐ROI tau and global amyloid change correlated with non‐memory change in Aβ+ OA. Tau and amyloid accumulation were not associated with structural change in OA.

4 December 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
LFLarissa Fischer
Larissa Fischer
DPDana M Parker
Dana M Parker
SMSamira Maboudian
Samira Maboudian
CFCorrina Fonseca
Corrina Fonseca
CTClaudia Tato-Fernández
Claudia Tato-Fernández
MSMichael Schöll
Michael Schöll
Despite extensive research, open questions about the biological underpinnings of Alzheimer’s disease (AD) remain. Neuroimaging biomarkers based on positron emission tomography (PET) and magnetic resonance imaging (MRI) offer in vivo insights into these complex biological changes and interactions. However, most evidence to date comes from cross-sectional studies, limiting our understanding of disease progression. Longitudinal studies enable the investigation of biological changes within individuals, revealing how pathology evolves over time. With this review, we provide an overview of how longitudinal imaging biomarker studies have advanced the field and how they can contribute to future research. We highlight longitudinal biomarker studies that have provided critical insights into disease trajectories, staging, and individual variability. We further assess longitudinal multimodal studies which have elucidated interactions between AD-specific pathology, amyloid-β and tau, and broader biological changes like neurodegeneration, neuronal dysfunction, vascular disease, and inflammation. Further, we discuss associations of brain changes with symptomatology and clinical outcomes and conclude with challenges and future directions.

15 November 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
RSRowan Saloner
Rowan Saloner
CFCorrina Fonseca
Corrina Fonseca
EPEmily W. Paolillo
Emily W. Paolillo
BABreton M. Asken
Breton M. Asken
NDNina A. Djukic
Nina A. Djukic
KCKaitlin B. Casaletto
Kaitlin B. Casaletto
Background and Objectives Synaptic dysfunction and degeneration is a predominant feature of brain aging, and synaptic preservation buffers against Alzheimer disease (AD) protein-related brain atrophy. We tested whether CSF synaptic protein concentrations similarly moderate the effects of axonal injury, indexed by CSF neurofilament light [NfL]), on brain atrophy in clinically normal adults. Methods Clinically normal older adults enrolled in the observational Hillblom Aging Network study at the UCSF Memory and Aging Center completed baseline lumbar puncture and longitudinal brain MRI (mean scan [follow-up] = 2.6 [3.7 years]). CSF was assayed for synaptic proteins (synaptotagmin-1, synaptosomal-associated protein 25 [SNAP-25], neurogranin, growth-associated protein 43 [GAP-43]), axonal injury (NfL), and core AD biomarkers (ptau181/Aβ42 ratio; reflecting AD proteinopathy). Ten bilateral temporoparietal gray matter region of interest (ROIs) shown to be sensitive to clinical AD were summed to generate a composite temporoparietal ROI. Linear mixed-effects models tested statistical moderation of baseline synaptic proteins on baseline NfL-related temporoparietal trajectories, controlling for ptau181/Aβ42 ratios. Results Forty-six clinically normal older adults (mean age = 70 years; 43% female) were included. Synaptic proteins exhibited small to medium correlations with NfL (r range: 0.10–0.36). Higher baseline NfL, but not ptau181/Aβ42 ratios, predicted steeper temporoparietal atrophy (NfL × time: β = −0.08, p < 0.001; ptau181/Aβ42 × time: β = −0.02, p = 0.31). SNAP-25, neurogranin, and GAP-43 significantly moderated NfL-related atrophy trajectories (−0.07 ≤ β9s ≥ −0.06, p9s < 0.05) such that NfL was associated with temporoparietal atrophy at high (more abnormal) but not low (more normal) synaptic protein concentrations. At high NfL concentrations, atrophy trajectories were 1.5–4.5 times weaker when synaptic protein concentrations were low (β range: −0.21 to −0.07) than high (β range: −0.33 to −0.30). Discussion The association between baseline CSF NfL and longitudinal temporoparietal atrophy is accelerated by synaptic dysfunction and buffered by synaptic integrity. Beyond AD proteins, concurrent examination of in vivo axonal and synaptic biomarkers may improve detection of neural alterations that precede overt structural changes in AD-sensitive brain regions.

24 January 2026 in Annals of Neurology
Verified
Journal Article
Open access
SMSamira A. Maboudian
Samira A. Maboudian
CFCorrina S. Fonseca
Corrina S. Fonseca
AMAdam C. Martersteck
Adam C. Martersteck
YCYishu Chao
Yishu Chao
YCYuheng Chen
Yuheng Chen
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Objective: Though it is widely known that tau deposition affects brain structure, the precise localization of these effects is poorly understood, especially in relation to gyral and sulcal anatomy. We investigated whether tau pathology in Alzheimer's disease (AD) preferentially affects sulci, and particularly sulcal depths. Methods: We analyzed 675 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with magnetic resonance imaging (MRI) and positron emission tomography (PET) data to investigate relationships between neocortical tau PET signal and cortical thickness. We then examined an advanced AD case with postmortem MRI and coregistered whole‐brain phospho‐tau staining for evidence of sulcal tau distribution in AD. Finally, in a sample of 187 cognitively unimpaired young and older adults with resting‐state functional MRI, we examined connectivity strength between tau‐vulnerable regions and the hippocampus across adulthood, prior to disease‐related cognitive decline. Results: Our findings revealed that tau‐related cortical thinning predominantly occurs in sulcal regions, especially the deepest parts. Postmortem histology confirmed preferential tau accumulation in sulcal depths. Additionally, connectivity analyses revealed that, across adulthood, these primarily sulcal regions most susceptible to tau‐related thinning also have stronger connectivity to the hippocampus, suggesting a role for network connectivity in the vulnerability of sulci to the effects of tau pathology later in life. Interpretation: These findings support the hypothesis that sulci, and particularly their depths, represent structurally and functionally vulnerable regions for tau deposition in AD. Understanding the mechanisms underlying this sulcal vulnerability provides insight into general principles driving regional susceptibility to pathology, and sheds light on the detrimental functional and cognitive effects of tau pathology. ANN NEUROL 2026;99:1343–1353

4 January 2026 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CFCorrina S. Fonseca
Corrina S. Fonseca
YCYishu Chao
Yishu Chao
RJRenaud La Joie
Renaud La Joie
GRGil D. Rabinovici
Gil D. Rabinovici
WJWilliam J. Jagust
William J. Jagust
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
INTRODUCTION: The spatial progression of longitudinal tau pathology has been inferred using cross‐sectional data, but longitudinal voxel‐wise analyses allow these patterns to be established without inference. METHODS: We pooled 1426 flortaucipir (FTP) positron emission tomography (PET) scans from 583 participants across the aging and Alzheimer's disease (AD) spectrum from four studies. Using longitudinal tau‐PET slope maps, we examined tau accumulation by clinical group and its associations with participant characteristics, baseline beta‐amyloid (Aβ), and tau. RESULTS: Tau accumulation was limited to temporoparietal cortices in unimpaired participants but widespread in patients. Baseline Aβ, entorhinal, and inferior temporal tau predicted progressively more severe tau accumulation patterns. Age, sex, and apolipoprotein E (APOE) ε4 had modest moderating effects. Aβ and early tau interactions showed synergistic effects. Greater tau accumulation was linked to worse follow‐up cognition than baseline. DISCUSSION: While Aβ influences early tau progression, baseline tau drives later progression. These results may guide future trials targeting tau accumulation at different disease stages. Highlights: Faster tau spread from temporal to frontal lobes was linked to clinical impairment. Global beta‐amyloid (Aβ), entorhinal, and inferior temporal gyrus (ITG) tau predicted progressively worse tau accumulation. Age, sex, and apolipoprotein E (APOE) had minimal effects on tau accumulation. Aβ and early tau burden interact synergistically to drive tau accumulation. More severe tau accumulation was linked to worse cognition at follow‐up than baseline.

6 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RJRenaud La Joie
Renaud La Joie
Marlene LinMarlene Lin
Marlene Lin
YWYingbing Wang
Yingbing Wang
DSDavid N. Soleimani-Meigooni
David N. Soleimani-Meigooni
TETara Ellingson
Tara Ellingson
GRGil D. Rabinovici
Gil D. Rabinovici
Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantitation across pipelines and visual reads for interpreting pre– and post-ATT amyloid PET. Methods : We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, including 41 paired scans. Centiloids were derived using FDA-cleared MIMneuro and two research pipelines (rPOP, CapAIBL) and compared using intraclass correlation coefficients (ICC). Clearance rates were estimated using linear mixed-effects models. Full TRAC was defined on post-ATT scans quantitatively (<11 Centiloids) or based on visual interpretation by 3 expert readers. Results : Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia). Centiloid agreement between pipelines was equally high pre– and post-ATT (both ICCs=0.90). Among paired scans (mean treatment duration, 16.7±4.6 months), clearance estimates were similar across pipelines and greater with donanemab (n=15 patients; between –62 and –60 Centiloids/year depending on the pipeline) than lecanemab (n=26; –38 to –36 Centiloids/year; all P<0.005). Among 54 post-ATT scans, between 44% and 57% were <11 Centiloids depending on pipeline, with 20 (37%) meeting this criterion across all 3 pipelines. In contrast, only 11%–19% were visually negative across readers, with 4 (7%) unanimously read as negative. Of the 20 post-ATT scans <11 Centiloids across all pipelines, 13 (65%) were considered positive by all readers, commonly with residual occipital binding. Conclusion : Centiloid quantitation was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials. However, quantitative and visual assessments were markedly discordant after ATT, with an unusually high proportion of scans <11 Centiloids remaining visually positive, warranting cautious interpretation of post-ATT Centiloid values. Larger studies should assess the clinical relevance of these findings and further develop robust approaches to establish full TRAC.